Your SlideShare is downloading. ×
Presentation  findings and recommendations on HIV, the law and treatment access.
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Presentation findings and recommendations on HIV, the law and treatment access.


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide
  • At end of 2010, 6 650 000 PWA receiving treatment globallyDespite this, less than 50% of PWA in need of treatment globally are receiving it, based on WHO revised guidelines of 350 CD4
  • Treatment 2.0 lists the taking advantage of TRIPs flexibilities as a key component of cost reduction
  • Transcript

    • 1. Findings and Recommendations on HIV, the law and Treatment Access: HIV/AIDS practice Meeting Dubai, 12 January 2012 Tenu Avafia HIV/BDP, NY
    • 2. Finding 1:TRIPS Flexibilities have increased generic competition Source: MSF (2010), Untangling the Web of Antiretroviral Price Reductions, 13th ed.
    • 3. Finding 2: Generic Competition has resulted in increased treatment scale up • 22-fold increase in treatment in 7 years • At end of 2010, 6 650 000 PWA were receiving treatment globally, about 47% of those in need • Only 23% of children have access to ART • 2011 HLM commitment of 15 million by 2015
    • 4. Finding 3: There is an Impending Treatment Crisis • India produces >85% of generic ARVs used by low and middle income countries globally • 2005 Indian Patents Act was amended to comply with TRIPS Agreement • 2010 UNDP study shows that more medicine patents being granted in India • Patenting of new medicines in India will affect availability of 2nd and 3rd generation ARVs in developing countries
    • 5. Finding 4: Countries will have to use Flexibilities to Sustain and increase Treatment Levels • Up to 95% of PWA on ART still on first generation treatment • Because of resistance, switch to second generation ARVs: some under patent 3.4x times more expensive, 3rd generation up to 23.4 times more expensive • TRIPS flexibilities can reduce cost of treatment for Hep C, and NCDs e.g. Cancers, cardiovascular diseases • Recommendation: Countries should adopt and utilize the TRIPS public health flexibilities • Explore new TRIPS flexibilities and modalities e.g. South-south
    • 6. Indonesia Oct 2004 GU (manufacture) -lamivudine, nevirapine 7-8 years (remaining patent term) 0.5% of the net selling value of ARVs to patent holder Malaysia Oct 2003 GU to import: didanosine; zidovudine; didanosine+zidovudine 2 years Offered 4% Thailand Nov '06 GU: to import/manufacture Efavirenz until 31 Dec. 2011 0.5% Thailand Jan '06 GU to import/manufacture: clopidogrel Patent expiry or no longer needed 0.5% Thailand Jan 2007 GU to import/manufacture : lopinavir/ritonavir Until 31st January 2012 0.5% of total sale value of the imported/locally produced Thailand Jan 2008 3 Government Use licence for cancer drugs Patent expiry or no longer needed 3-5% Brazil May 2007 GU to import efavirenz 5 years 1.5%
    • 7. Finding 5:The Emergence of IP enforcement agenda is impeding access to treatment • Several TRIPS+ FTAs involving US, EU, Japan and EFTA countries • TRIPS + measures can impede the use of TRIPS flexibilities, often resulting in higher drug costs • UNDP model shows US CAFTA FTA resulting in 40% increase a year • DE resulted in 2 generic versions of LPV/r being de-registered in Ukraine • Recommendation: Countries should avoid signing TRIPS+ FTAs that impedes access to treatment
    • 8. Finding 5 continued: IP Enforcement Agenda • Initiatives to use TRIPS Flexibilities could be endangered by proliferation of “anti-counterfeiting” legislation: – Tanzania, Subsidiary Merchandise Marks Act, 2008; – Kenya , Anti-Counterfeiting Act ,2008; – Uganda, discussing a Counterfeit Goods Bill since 2008, Revived in Parliament in late 2011 – Reports of Legislation being deliberated in some southern African countries • Draft EAC Anti-counterfeit Act being discussed • Several stakeholders have expressed concerns about impact • Recommendation: Countries when passing domestic legislation should not adopt measures that could impede access to treatment
    • 9. Finding 6: Current IP system does not Stimulate innovation for ARVs, Communicable diseases, NTDs • Despite the global increase in patenting in recent years, there has been a decrease in innovation pipeline • Current IP system is not stimulating innovation for ARVs (FDCs and Pediatric) and NTDs • Recommendation: Countries should explore systems outside of current IP system to stimulate innovation in pharmaceutical products • IP system should only reward genuine innovation • Possibilities include patent pools, R&D treaty, open source innovation platforms
    • 10. What can UNDP do in terms of: • Legislative review and reform • Judicial sensitization • Parliamentary training • Coordinating national working groups • Working with Patient groups/treatment advocates • Providing technical assistance